New Teams Formed and Projects Awarded at Retreat
The YCC Annual Retreat was held on Wednesday May 21st at West Campus Conference Center. Thank you to all of the members who cleared their schedule for the day to join us. This was a highly interactive event, featuring group discussions and scientific presentations from Theodore Holford, Valentina Greco, and Daniel Petrylak.

The afternoon peaked when teams of members were formed to create and present research project proposals for Yale Cancer Center Accelerated Research in Cancer (ARC) Grants for $50k. Attendees were randomly grouped and had thirty minutes to generate a research proposal with the requirements of a single Principal Investigator and collaboration between three or more investigators. 9 PIs presented their team’s proposals and all attendees voted. The top two groups were awarded a grant.

Congratulations to:
Targeting Melanoma Brain Metastases with Novel Therapeutics

PI: Marcus Bosenberg
Karen Anderson
Peter Glazer
Harriet Kluger
Don Nguyen
Manoj Pillai

Discovery of PD-L1 Axis Modulators in Triple Negative Breast Cancer (TNBC)

PI: David Rimm
Maysa Abu-Khalaf
Henk DeFeyter


Interested in immunotherapy for melanoma at #asco14; you won’t want to miss this LBA and discussion.

Tune in to @YaleCancer Answers at 6 PM @WNPR for a program highlighting brain tumor awareness month. #btsm pic.twitter.com/nmOfObyWKP

What you don’t know about sun could hurt you! Our sun exposure quiz: http://ow.ly/wG6gd #skincancer @YaleCancer pic.twitter.com/FiOkTsEPWq

Register for @SurvivorsDay on June 11 with @ClaireNewHaven @CitySeedNH @YNHH. #closetoafree http://bit.ly/YaleCSD pic.twitter.com/Wr9eAa19m0
Frank Slack  
Yong Zhu

**Oncology Nursing Awards Presented**

I was pleased to join Cathy Lyons, Executive Director of Patient Care Services at Smilow Cancer Hospital, and the rest of the nursing leadership team last week to present the 2014 Oncology Nursing Awards as part of May's Oncology Nursing Month to recognize a few of the amazing nurses who care for our patients with compassion, dedication, and skilled knowledge each day. Congratulations to this year's award winners!

Debra Nadaskay, recipient of the Nursing Award for Clinical Excellence, with Cathy Lyons

Rebecca Halpern, recipient of the Oncology Research Award with Cathy Lyons

---

Dr. Dan Petrylak on unprecedented findings in bladder study.  
http://bit.ly/1ksL8L2

@aneeschagpar:  
Awesome to be a guest of honor at @AmericanCancer webinar on #LGBT cancer issues. Help us w/ survey at http://www.healthequality.org @YaleCancer

@oncaprn:  
Advancements in Melanoma Present New Challenges for Nurses  
http://shar.es/SQGjO via @OncLive @yalenurse @YaleCancer

@YNHH:  
Ready for the sun? Listen to latest on #skincancer from @YaleCancer and #Smilow:  
http://ow.ly/wG30z  #melanoma  
pic.twitter.com/jXfY4eH98k

---

Join Yale Cancer Center on Facebook

---

LATEST POSTS:

May is Brain Tumor Awareness Month. Tune in to Yale Cancer Center Answers tonight at 6 PM on WNPR to listen to an interview with Dr. Jennifer Moliterno Gunel on brain tumor detection, treatment, and new advances from Smilow Cancer Hospital at Yale-New Haven.
Since 2011, Annie Garcia Kaplan, a 9-year breast cancer survivor, has volunteered at the annual Closer to Free: A Ride for Smilow Cancer Hospital at Yale-New Haven. Annie, however, has been no ordinary volunteer; she and her group started the tradition of the Smilow Salute, a memorable celebration where patients and staff members cheer on the riders at the entrance to Smilow Cancer Hospital during the Ride’s first mile.

Meet Dr. Steven Gore, Director of Hematological Malignancies, who recently joined Smilow Cancer Hospital at Yale-New Haven. In this season’s recently released Centerpoint Magazine, Dr. Gore discusses treatment advances for myelodysplastic syndrome and his goals for the upcoming year.

Yale Cancer Center Participation at ASCO
I am looking forward to seeing many of you at the ASCO Annual meeting in Chicago next week. If you will be in attendance at the meeting, please take the time to support our colleagues. A full list of participation (first or
last authors from YCC) is below. Please contact Renee Gaudette to have your presentations added to the online list. You can download the list here.

**Oral Abstract Sessions**

**Saturday, May 31; 1:15 PM to 4:15 PM**

**S100bc**

*Effect of weight loss intervention on inflammatory and metabolic markers in breast cancer survivors: The lifestyle, exercise, and nutrition (LEAN) study.*

Erika Loftfield, Maura Harrigan, Fangyong Li, Brenda Cartmel, Yang Zhou, Mary Playdon, Lingeng Lu, Tara Beth Sanft, Melinda Irwin

**Abstract:** 1505

---

**Monday, June 2; 8:00 AM to 11:00 AM**

**E450**

*The KRAS-variant and cetuximab response in RTOG 0522*

Joanne B. Weidhaas, Jonathan Harris, Rita Axelrod, Adel K. El-Naggar, Anurag Singh, Thomas Galloway, David Raben, Dian Wang, Terence S. Herman, R. Jeffrey Lee, Rafael Ricardo Manon, Omar Yumen, Qiang Zhang, Christine H. Chung

**Abstract:** 6000

---

**Monday, June 2; 9:24 AM - 9:36 AM**

**Location:** E354a

*Monoclonal Antibodies in B-Cell Malignancies*

Madhav V. Dhodapkar

---

**Monday, June 2; 9:45 AM to 12:45 PM**

**E Hall D2**

Session Co-chair: Scott N. Gettinger

---

**Monday, June 2; 3:00 PM to 6:00 PM**

**E Arie Crown Theater**

*Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).*

Mario Sznol, Harriet M. Kluger, Margaret K. Callahan, Michael Andrew Postow, Ruth Ann Gordon, Neil Howard Segal, Naiyer A. Rizvi, Alexander M. Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda L. Ralabate, Angel L. Rivera, Stephanie Anne Kronenberg, Blessing Agunwamba, William Feely, Quan Hong, Suba Krishnan, Ashok Kumar Gupta, Jedd D. Wolchok

**Abstract:** LBA9003^®

---

**Monday, June 2; 3:00 PM to 6:00 PM**

**S100bc**

*Challenges in Assessing Tumor Heterogeneity*

---

During a routine screening, David was diagnosed with prostate cancer. In his late 60s, David was in denial at first; he had not been sick since the age of 9 and felt just fine. He sought the care of Yale Cancer Center's Dr. Richard Peschel and Dr. John Colberg. Both Dr. Peschel and Dr. Colberg dealt with whatever bothered David before it became a bigger issue. David says, "They didn't scare me, but still remained honest."

---

Dr. Anees Chagpar (3rd from left) along with other School of Management graduates today outside Evans Hall.

---

Let's face it, with crunchy shells and creamy fillings, cannoli are irresistible. Thanks to the New Haven Cannoli Truck, you can now satisfy all of your cannoli cravings in addition to supporting cancer research and care.

The Cannoli Truck, which is owned and operated by the family-owned, Guilford-based Meriano's Bake Shoppe, donates a portion of all proceeds to the Thoracic Oncology Program at Smilow Cancer Hospital at Yale-New Haven.
Clinical Science Symposiums
Saturday, May 31; 8:30 AM
E Hall D 1
Breaking the Barrier of Acquired Resistance
Thomas Lynch

Saturday, May 31; 3:00 PM to 4:30 PM
E Arie Crown Theater
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC)
Abstract: 5011

Saturday, May 31; 3:00 PM to 4:30 PM
E Arie Crown Theater
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial
Toni K. Choueiri, Mayer N. Fishman, Bernard J. Escudier, Jenny J. Kim, Harriet M. Kluger, Walter Michael Pimack, Leonard Joseph Appleman, Lawrence Fong, Charles G. Drake, Lewis J. Cohen, Shivani Srivastava, Maria Jure-Kunkel, Quan Hong, John F. Kurland, Mario Sznol
Abstract: 5012

Education Sessions
Saturday, May 31; 1:15 PM to 2:30 PM
Location: S100a
Session Chair: Mario Sznol
One Size Does Not Fit All: What We Have Learned from Immunotherapy Trials
Mario Sznol

Sunday, June 1; 4:45 PM to 6:00 PM
Location: E Hall D1
Session Chair: Scott N. Gettinger
Future Directions in Immunotherapies: Rationale and Risk
Scott N. Gettinger

Tuesday, June 3; 8:40 AM to 9:00 AM

Events

May 23; 12:00 PM
YCC Research in Progress Meeting
NP4-101A
Dissemination of Precision Breast Cancer Care: Understanding Equity and Appropriateness
Cary Gross, MD
Learn More >>

May 25; 6:00 PM
Yale Cancer Center Answers
WNPR
Reconstructive Surgery for Head and Neck Cancer
Saral Mehra, MD, MBA
Learn More >>

May 27; 9:30 AM
Pathology Research in Progress Talks
Brady Auditorium, BML-131
TBA
Ryan Jensen, PhD and Goran Micevic
Learn More >>

May 27; 12:00 PM
Yale Cancer Center/Cancer Genetics and Genomics Faculty Lunch
Breast Medical Oncology Conference Room, Suite 120, Room 129
Spectrometry in the Diagnosis of Melanocytic Lesions
Rossitza Lazova, MD
Location: S406
Should a Diagnosis of Triple-Negative Breast Cancer Affect Locoregional Therapy Decision Making?
Meena S. Moran

Tuesday, June 3rd; 10:00 AM - 10:15 AM
Location: S100bc
Revising the Role of Chemotherapy in Prostate Cancer
Daniel Peter Petrylak

Poster Highlight Sessions
Friday, May 30; 1:00 PM to 4:00 PM
Location: S102
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206
Harriet M. Kluger, Susan Halabi, Nicole C Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, Daniel J. George
Abstract: 4532

Friday, May 30; 4:30 PM to 5:45 PM
Location: S100bc
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206
Harriet M. Kluger, Susan Halabi, Nicole C Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, Daniel J. George
Abstract: 4532

Saturday, May 31; 1:15 PM to 4:15 PM
Location: E354b
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC)
Abstract: 5023

Saturday, May 31; 4:45 PM to 6:00 PM
Location: E Arie Crown Theater
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer
Abstract: 5023

**Monday, June 2; 8:00 AM to 11:00 AM**
Location: S102

*Effect of exercise on weight, body fat, and serum inflammatory biomarkers in breast cancer survivors with aromatase inhibitor arthralgias: The hormones and physical exercise (HOPE) study.*
Melinda Irwin, Brenda Cartmel, Cary Gross, Fangyong Li, Xiaopan Yao, Martha Fiellin, Elizabeth Ercolano, Maura Harrigan, Yang Zhou, Tara Beth Sanft, Kathryn Schmitz, Dawn Hershman, Jennifer Ligibel

**Abstract:** 9536

**Monday, June 2; 11:30 AM to 12:45 PM**
Location: S100bc

*Effect of exercise on weight, body fat, and serum inflammatory biomarkers in breast cancer survivors with aromatase inhibitor arthralgias: The hormones and physical exercise (HOPE) study.*
Melinda Irwin, Brenda Cartmel, Cary Gross, Fangyong Li, Xiaopan Yao, Martha Fiellin, Elizabeth Ercolano, Maura Harrigan, Yang Zhou, Tara Beth Sanft, Kathryn Schmitz, Dawn Hershman, Jennifer Ligibel

**Abstract:**

**Monday, June 2; 1:15 PM to 4:15 PM**
Location: S102

*Estimating the impact of screening on three decades of cervical cancer incidence*
Daniel Xiao Yang, Pamela R. Soulou, Brigette Davis, Cary Gross, James B. Yu

**Abstract:** 1518

**Monday, June 2; 4:45 PM to 6:00 PM**
Location: E Hall D1

*Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer.*
Jason R. Brown, Yalai Bai, Veerle Bossuyt, Christian Nixon, Donald R. Lannin, David L. Rimm

**Abstract:** 1027

---

**Employment Opportunities**

Success in any clinical research endeavor, but especially in cancer research, requires the most qualified, dedicated staff, committed to excellence and the mission of Yale Cancer Center. The combination of education, oncology research experience, and exceptional nursing skills is enormously difficult to find. Your participation, as knowledgeable colleagues, is invaluable at this time.

Should you know individuals with outstanding clinical research nursing experience, and who are ready to join our team, please direct resumes to Sandra Greer, Sr. Staffing and Career Development Representative or call (203) 432-5822. All referrals will be held in strictest confidence.

---

**Submissions**

Please submit your recent publication and grant announcements to:

**Renee Gaudette**
Director, Public Affairs and Marketing
reneegaudette@yale.edu
Nixon, Donald R. Lannin, David L. Rimm

Abstract: 1027

Location: S100a

*Estimating the impact of screening on three decades of cervical cancer incidence*

Daniel Xiao Yang, Pamela R. Soulos, Brigette Davis, Cary Gross, James B. Yu

Abstract: 1518

Tuesday, June 3; 8:00 AM to 11:00 AM

Location: E354b

*First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.*

Scott N. Gettinger, Frances A. Shepherd, Scott Joseph Antonia, Julie R. Brahmer, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Naiyer A. Rizvi

Abstract: 8024

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC

Naiyer A. Rizvi, Laura Quan Man Chow, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Scott N. Gettinger

Abstract: 8022

Tuesday, June 3; 11:30 AM to 12:45 PM

Location: E450

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

Scott N. Gettinger, Frances A. Shepherd, Scott Joseph Antonia, Julie R. Brahmer, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Naiyer A. Rizvi

Abstract: 8024

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC

Naiyer A. Rizvi, Laura Quan Man Chow, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Scott N. Gettinger

Abstract: 8022

Poster Sessions: S Hall A2
Friday, May 31; 8:00 AM to 11:45 AM

Monitoring changes in circulating tumor DNA in gastrointestinal malignancies using a novel next-generation sequencing method.

Abstract: 3645

E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC)
Howard S. Hochster, Paul J. Catalano, Edith P. Mitchell, Deirdre Jill Cohen, Peter J. O'Dwyer, Al Bowen Benson

Abstract: TPS3665

Evaluation of the diagnostic accuracy of cervical biopsy and determination of associated risk factors for positive margin status in recurrent cervical dysplasia after loop or conization
Diana Peta-gay English, Monica Pasternak, Janelle Warmington, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro Santin, Thomas J. Rutherford

Abstract: 5609

Saturday, May 31; 1:15 PM - 5:00 PM

Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC)

Abstract: 8064

Clinical significance of TILs subtypes in non-small cell lung cancer
Kurt A. Schalper, Jason Brown, Joseph Francis McLaughlin, Roy S. Herbst, David L. Rimm

Abstract: 8082

Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma.

Abstract: 8093

The KRAS-variant and treatment response in BATTLE-1
Abstract: 8135

BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC)

Abstract: 8042

Diffusion of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) in the Medicare population, 2007-2009
James B. Yu, Pamela R. Soulos, Laura D. Cramer, Roy H. Decker, Anthony W. Kim, Cary Philip Gross

Abstract: 7575

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC)
Scott N. Gettinger, Lyudmila Bazhenova, Ravi Salgia, Corey J. Langer, Kathryn A. Gold, Rafael Rosell, Alice Tsang Shaw, Glen J. Weiss, Narayana I. Narasimhan, David J. Dorer, Victor M. Rivera, Tim Clackson, Frank G. Haluska, D. Ross Camidge

Abstract: 8047

A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.
Roy S. Herbst, Alfonso Gurpide, Veerle Surmont, Dong-Wan Kim, Saima Naheed Waqar, Judith Herder, Dae Ho Lee, Enric Carcereny, Noemi Reguart, John M. Wallmark, Suresh S. Ramalingam, Corey J. Langer, Gregory M. Lubiniecki, James Knowles, Honghong Zhou, Mary Elizabeth Hanson, Paul Baas

Abstract: TPS8124

Postoperative chemotherapy as effective as preoperative for N2-positive stage III non-small cell lung cancer
Daniel J Boffa, Jacquelyn Hancock, Amy Moreno, Joshua Rosen, Anthony W. Kim, Frank C. Detterbeck;

Abstract: 7533

Clinical trials of MPDL3280A (anti-PDL1) in patients (pts)
with non-small cell lung cancer (NSCLC)
Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel

Abstract: TPS8123

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis

Abstract: 8112

Sunday, June 1; 8:00 AM to 11:45 AM
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.
Ami P. Jhaveri, Maysa M. Abu-Khalaf, Michael DiGiovanna, Lajos Pusztai, Erin Wysong Hofstatter, Tara Beth Sanft, Noelle Marie Sowers, Bonnie Lurie, Andrea Silber, Debra S. Brandt, Howard S. Hochster, Jill Lacy, Stacey Stein, Gina G. Chung

Abstract: 2561

Monday, June 2; 8:00 AM to 11:45 AM
Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients
Balazs Gyorffy, Thomas Karn, Zsofia Sztupinszki, Boglarka Weltz, Volkmar Muller, Lajos Pusztai

Abstract: 1065

Monday, June 2; 1:15 PM to 5:00 PM
Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement.
Francine M. Foss, Madeleine Duvic, Adam Lerner, Alain Rook, Sean Whittaker, Ellen J. Kim, Youn H. Kim

Abstract: 8575

A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases
Daniel Peter Petrylak, Julie A. Rosenberg, Vittorio Luigi
Garosi, Jonathan Siegel, Jonathan Goldin  
**Abstract:** TPS5103

*Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL)*  
Francine M. Foss, Barbara Pro, H. Miles Prince, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Steven M. Horwitz, Bertrand Coiffier

**Abstract:** 8563

*Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.*  
Tisheeka Graham-Steed, Pamela R. Soulos, Natalie Dearing, John Concato, Mary Tinetti, Cary Philip Gross

**Abstract:** 5056

*Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS)*  
Roxanne Jimmy Wadia, Xiaopan Yao, Yanhong Deng, Jia Li, Steve Maron, Donna Connery, Handan Gunduz-Bruce, Michal G. Rose

**Abstract:** 6542

*Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Children’s Oncology Group (COG) AALL0932*  
Nina S. Kadan-Lottick, Xiaomin Lu, Marilyn Hockenberry, Moira K. Whitley, Stephen Hunger, Meenakshi Devidas, Naomi Joan Winick, Reuven J. Schore, Anne L. Angiolillo, Kirsten K. Ness

**Abstract:** 7056

*Publication Only Abstracts*

**Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).*  
Edward Samuel James, Xiaopan Yao, Xiangyu Cong, Jia Li, Carol Hahn, Kristin Kaley, Jeremy S. Kortmansky, Neal A. Fischbach, Bryan William Chang, Ronald R Salem, Charles Cha, Stacey Stein, Howard S. Hochster, Jill Lacy

**Abstract:** e15226

*Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.*  
Esther Park, Maysa M. Abu-Khalaf, Christos Hatzis, Johanna M. LaSala, Andrea Silber, Erin Wysong
Hofstatter, Tara Beth Sanft, Raymond Russell
Abstract: e11501

A multianalyte algorithm PCR-based gene blood test compared to single analyte ELISA-based blood tests for neuroendocrine tumor detection
Irvin Mark Modlin, Daniele Alaimo, Stephen Callahan, Nancy S. Teixeira, Lisa Bodei, Ignat Drozdov, Mark S. Kidd
Abstract: e15168

Effect of weight history on ability to lose weight after a 6-month randomized controlled weight loss trial in overweight breast cancer survivors: The lifestyle, exercise, and nutrition (LEAN) study
Tara Beth Sanft, Maura Harrigan, Brenda Cartmel, Mary Playdon, Yang Zhou, Erikka Loftfield, Melinda Irwin
Abstract: e20591

Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer
Leona C Han, Nilay Shah, Cary Philip Gross, Joseph S. Ross, Paul Linh Nguyen, Marc C. Smaldone, Jon Charles Tilburt, James B. Yu, Quoc-Dien D Trinh, R. Jeffrey Karnes, Weranja Kalana Bodhisiri Ranasinghe, Maxine Sun, Simon P. Kim
Abstract: e16085

Out-of-pockets costs for patients receiving targeted agents for metastatic renal cell carcinoma
Simon P. Kim, Cary Gross, Robert Abouassaly, Sarah P. Psutka, Holly K. Van Houten, Robert Houston Thompson, Marc C. Smaldone, Quoc-Dien D Trinh, Maxine Sun, Leona C Han, Nilay Shah
Abstract: e15598

Celebration to Honor Frank Slack
Dr. Frank Slack recently accepted a new position at Harvard and will be leaving Yale later this summer. Yale Cancer Center is indebted to Frank for his collegiality, scientific achievements, and especially his leadership of the Cancer Genetics and Genomics Research Program.

Please join us to celebrate his accomplishments and wish Frank well:

Wednesday, June 4, 2014
4:30 - 5:30 pm
BCMM 206/208
Boyer Center for Molecular Medicine
295 Congress Ave., 2nd Floor
Please send your RSVP to hilary.prosnitz@yale.edu

**Medical Oncology and Hematology Teaching Prizes**
Yale Cancer Center is accepting nominations from current fellows for the David S. Fischer Teaching Award for the best teacher/mentor from both the medical oncology faculty and the hematology faculty, including the medical staff at the West Haven Veterans Administration Hospital. Please consider effectiveness as a teacher and mentor, involvement in clinical conferences and lectures, and "bedside teaching" when choosing your nominations. The awards will be given out at the graduation dinner. Please contact Savannah Woods for a nomination form or for more information. Nominations are due to Savannah by June 1.

**Notables**

**Douglas E. Brash**, Professor of Therapeutic Radiology and a member of our Radiobiology and Radiotherapy Program, will be awarded the **2014 Finsen Medal of the International Union of Photobiology**. The IUP Congress presents the medal, recognizing lifetime achievement in photobiology, every five years. It commemorates Niels R. Finsen, recipient of the 1903 Nobel Prize in Physiology or Medicine for his studies on phototherapy of cutaneous tuberculosis. Dr. Brash's laboratory has elucidated many of the steps through which sunlight causes skin cancer.

**Marianne Davies** and **Rebecca Sipples** recently completed their Doctorates of Nursing Practice (DNP) degrees at the **MGH Institute of Health Professions**. Marianne's areas of concentration were: health professions education and nursing leadership and Rebecca's were: health professions education and global health. By the year 2025, all nurse practitioner programs will transition to doctoral level preparation.

**Research in the News**

**Yale Cancer Center Studies Find Lifestyle Changes Improve Biomarkers Associated with Breast Cancer Recurrence and Mortality**
A pair of Yale Cancer Center interventional studies involving breast cancer survivors found that lifestyle changes in the form of healthy eating and regular exercise can decrease biomarkers related to breast
cancer recurrence and mortality. The abstracts are scheduled to be presented at the 2014 annual meeting of the American Society of Clinical Oncology.

“The findings of both studies support a growing body of research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,” said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both studies. Read More >>

Development Update

Smilow Cancer Hospital received a pledge from a grateful family to establish “The 11th Fund for NP-11 and Day Hospital Nurses and Staff.” Becky Gronlund was treated for leukemia over several months at Smilow, and her husband Wayne and family, including stepson Quentin, became especially close with the nurses and staff on NP-11, where Becky spent her last weeks, as well as in the Day Hospital on NP-7. Wayne is very grateful for the wonderful care shown to him, his wife, and his family during this extremely challenging time, and wanted to give back to everyone to show his deep appreciation. The Fund was named because Becky's life number was 11 (among other astounding facts she was born on 11/11/65...6+5=11..., her son was born on the 11th, her mother was born on the 11th, her street addresses at 2 separate residences were #11, and she was treated on NP-11). The Fund will be used for NP-11 and Day Hospital nurses and staff and for morale boosters, team building initiatives, as well as ways to better cope with the losses experienced by NP-11 and Day Hospital nurses and staff on a regular basis.

Congratulations and heartfelt appreciation to everyone involved for making such an impact on this family during their time of crisis and grief, and for the exceptional collaborative effort between staff and the YNHH Development Office.

Employee Profile:
Clare Garguilo

The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff to meet our patient care, research, education, and outreach goals. The staff profiled are
examples of the great work being done here, and the dedication and values we possess.

To suggest someone to be profiled, please contact Emily Fenton.

Earlier this month, Clare Garguilo celebrated her 15th anniversary of employment at Yale. In those fifteen years she has worked with students, professors, and physicians. Starting as a temp in Graduate Studies she worked primarily with Yale students, and then moved to the business side and is currently a Financial Assistant in the Yale Cancer Center Business Office. In her role she is responsible for assisting accountants with finances related to Medical Oncology, Hematology, Palliative Care, the Smilow Cancer Hospital Care Centers, and Neuro-Oncology.

Clare’s main responsibilities include assisting with iExpense reports and JSA’s. She makes sure that everything is charged correctly and that all the back-up documentation required is there. JSA’s are filed when a new expense is created and require authorization before they can be sent for processing. For this task, Clare must work directly with office administrators, the Accounts Payable Office, research lab assistants, the Procurement Department, etc. in order to ensure all money is accounted for. She explained that this requires a lot of attention to detail and focus for each report.

In the three years that Clare has been with the Cancer Center she explained that she has grown and learned the most in the shortest amount of time. Having taken advantage of all the opportunities offered to her, Clare has knowledge of many of the different facets at Yale and was able to work her way up to managing finances. "I am so grateful for the opportunities I have been given working at Yale. I have cultivated so many lasting and wonderful relationships and have gained so much valuable knowledge along the way," said Clare.

Funding and Award Opportunities

Pew-Stewart Scholars for Cancer Research Program

The Pew-Stewart Scholars for Cancer Research Program supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The award provides $240,000 in flexible support-$60,000 per year for a four-year period. Through the generosity of the
Alexander and Margaret Stewart Trust, Pew was able to expand the Scholars program in 2014 to add an additional five researchers each year to be named Pew-Stewart Scholars for Cancer Research.

Yale Cancer Center members who want to be considered for the Pew-Stewart Scholars for Cancer Research Program should send Daniel DiMaio their CV and a one page research summary by June 27th.

Damon Runyon Fellowship Award
The Damon Runyon Fellowship Award is designed to provide early career scientists with resources to hone their cancer research skills and explore their own ideas while working with mentors in top universities and cancer research centers. Awards are intended to support the fellow under direct supervision of the sponsor.

The award provides a stipend of $50,000 per year for three years for Level I funding, and $60,000 per year for three years for Level II funding. (Physician-scientists who have completed their residencies, clinical training, and are board eligible will receive Level II funding.) The award may not be used for institutional overhead or indirect costs. Fellows also receive an annual $2,000 expense allowance for educational and scientific expenses.

Application Deadline: August 15, 2014
Learn More >>

Pew Scholars Program in the Biomedical Sciences
For basic and clinical investigations relevant to the advancement of human health. Strong preference for creative and innovative approaches; risk-taking is encouraged.

- For individuals who will hold a full-time appointment at the rank of assistant professor by November 1, 2014, but who will not have been in such an appointment form more than 3 years as of July 1, 2014.
- 60,000 per year for 4 years. ($240,000)

Application Deadline: June 16, 2014
Learn More >> (PDF)

Searle Scholars Program

- To pursue independent research careers in biochemistry, cell biology, genetics, immunology, neuroscience, pharmacology, or related areas in
chemistry, medicine, and the biological sciences.

- For assistant professors who began their first appointment on or after July 1, 2013.

$100,000 per year for 3 years. ($300,000)

**Application Deadline:** June 16, 2014

Learn More >> (PDF)

Gabrielle's Angel Foundation for Cancer Research Medical Research Grants

- To support the conduct of innovative and insightful medical research on the hematologic malignancies.
- Funds are provided for clinical or basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies for patients with leukemia, lymphoma and related cancers of the blood.
- For assistant professors (or equivalent) with the MD or PhD.

$225,000 to be used over a period of 3 years. ($225,000)

**Application Deadline:** June 16, 2014

Learn More >> (PDF)

The Hartwell Foundation 2014 Individual Biomedical Research Award

For early-stage, innovative, cutting-edge, and high risk biomedical research that has the potential to be transformative.

- Proposed research should not yet have qualified for significant funding from outside sources.
- **Research should benefit children of the United States.**
- Investigators whose prior research may not have focused on benefiting children, but who now propose a relevant project benefiting children, are also encouraged to apply.
- For U.S. citizens with a full-time faculty appointment.

$100,000 per year for 3 years. ($300,000)

**Application Deadline:** July 15, 2014

Learn More >> (PDF)

AGA Foundation - 2014 Funderburg Research Award in Gastric Cancer
The American Gastroenterological Association is inviting applications for the 2014 Funderburg Research Award. The award is designed to support an established investigator working on novel approaches in gastric cancer research, including the fields of gastric mucosal cell biology, regeneration and regulation of cell growth (not as they relate to peptic ulcer disease or repair), inflammation (including Helicobacter pylori) as precancerous lesions, genetics of gastric carcinoma, oncogenes in gastric epithelial malignancies, epidemiology of gastric cancer, etiology of gastric epithelial malignancies, or clinical research in the diagnosis or treatment of gastric carcinoma. Please note, AGA membership is required at the time of application submission. Funding up to $100,000 over 2 years.

Application Deadline: August 29, 2014
Learn More >>

Alex’s Lemonade Stand Foundation Reach Awards
Our Reach Awards are designed to move hypothesis-driven research toward the clinic. The goal of this award is to support selected “late translational” studies needed to ultimately initiate a clinical trial. A successful application will identify an unmet clinical need relevant to the care of pediatric cancer patients and describe how the proposed project will allow for the pre-clinical research to be translated to the clinic while keeping broader clinical testing and implementation in view. Maximum of $250,000 in total costs awarded over two years.

Application Deadline: May 30, 2014
Learn More >>

Lung Cancer Research Foundation Grants
Support research on innovate strategies for better treatments, screening, and prevention of all cancers of the lung. These awards are designed to provide critical seed support for cutting-edge scientific research on all lung cancers and will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes. Up to $50,000 for 1 year.

Application Deadline: June 16, 2014
Learn More >>

Department of Defense Breast Cancer Research Program
Era of Hope Scholar Award
Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship,
medical residency, clinical fellowship) as of the application submission deadline

- Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the "best and brightest" in their fields.
- PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.
- PIs should exhibit strong potential for leadership in the breast cancer community
- PIs must include breast cancer advocates on their research team.
- Maximum funding of $2.5M for direct costs (plus indirect costs)
- Period of performance not to exceed 5 years

**Letter of Intent Deadline:** August 1, 2014  
**Application Deadline:** August 15, 2014  
**Learn More >>**

---

**Recent Publications**

**Common contaminants in next-generation sequencing that hinder discovery of low-abundance microbes.**  
Laurence M, Hatzis C, Brash DE.  
**Read More >>**

**In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas.**  
Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL.  
**Read More >>**

**Tea, coffee, and caffeine and early-onset basal cell carcinoma in a case-control study.**  
Ferrucci LM, Cartmel B, Molinaro AM, Leffell DJ, Bale AE, Mayne ST.  
**Read More >>**

**Clinicopathologic features and survival in Spitzoid malignant melanoma and conventional malignant melanoma.**  
Semkova K, Lott JP, Lazova R.  
**Read More >>**

**Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells.**


"Would you test your children without their consent?" and other sticky dilemmas in the field of cancgrogenetic testing. Brierley KL, Bonadies DC, Moyer A, Matloff ET. Fam Cancer. 2014 May 8. Read More >>